Get regular updates to your inbox.
A carbohydrate molecule derived from marine bacteria was able to reduce inflammation in the brain, reverse metabolic dysfunction, and preserve brain tissue integrity in a mouse model of Sanfilippo syndrome type A, according to a new study. These benefits corresponded to an easing of motor deficits in the mouse…
Standardized tests that measure memory, motor function, and well-being can be used to track the progression of neurological dysfunction in a mouse model of Sanfilippo syndrome type A, a study shows. “Our data show that the water cross maze, hind-limb gait, nest building, and burrowing are useful assessments to…
JCR Pharmaceuticals has won permission from officials in Germany to start a Phase 1/2 clinical trial of JR-441, an experimental therapy designed to deliver to the brain a working version of the enzyme that’s missing in Sanfilippo syndrome type A. The Paul-Ehrlich Institute (PEI), an agency of the…
Researchers are calling for individualized clinical trials that would test the effects of anti-inflammatory therapies for Sanfilippo syndrome and related conditions. A team of scientists from Europe has published a paper that outlines how such trials can be conducted and offered recommendations for specific therapies to test in specific…
Tralesinidase alfa, an experimental enzyme replacement therapy for people with Sanfilippo syndrome type B, was safe and showed good brain distribution in non-human primates, specifically cynomolgus monkeys, a new study found. The treatment was equally well tolerated regardless of dose, duration of the infusion, or formulation. According to…
The National MPS Society will host its Maritime Gala May 13 on the San Francisco Bay in Tiburon, California, at the historic Corinthian Yacht Club to raise funds for its family support and research programs. The event also observes International MPS Awareness Day, observed annually on May…
A newly identified mutation was found in a boy from Kosovo with Sanfilippo syndrome type B alongside a well-known disease-causing mutation, a recent study reported. Because this mutation had never been reported, the researchers said more research is needed to determine its frequency in the Balkan region of southern…
Light-sensing cells in the eyes become damaged and die in Sanfilippo syndrome type C before the onset of behavioral symptoms, a new study indicates. Issues related to vision “may be the first truly distinctive symptom” of Sanfilippo for these patients, which suggests “better disease awareness among ophthalmologists could play…
The investigational, brain-penetrating enzyme replacement therapy DNL126 was found to correct neurological signs of Sanfilippo syndrome type A in a mouse model, according to its developer, Denali Therapeutics. Now, the biopharmaceutical company plans to seek U.S. Food and Drug Administration permission — via an investigational new drug application…
Four out of the five children with Sanfilippo syndrome type A in a Phase 1/2 clinical trial have continued to gain cognitive skills — which in three were similar to healthy children — after being given OTL-201, an experimental gene therapy being developed by Orchard Therapeutics. The children…
Get regular updates to your inbox.